Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Public ClinicalTrials.gov record NCT05727176. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
Study identification
- NCT ID
- NCT05727176
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Interventions
- TAS-120 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2023
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Dec 28, 2025
2023 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego UCSD - Moores Cancer Center | La Jolla | California | 92093 | Recruiting |
| Tampa General Hospital Cancer Institute | Tampa | Florida | 33606 | Recruiting |
| Henry Ford Health System | Detroit | Michigan | 48202 | Recruiting |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | Withdrawn |
| Texas Oncology | Abilene | Texas | 79606-5208 | Recruiting |
| The Liver Institute at Methodist Dallas Medical Center | Dallas | Texas | 75203 | Recruiting |
| Texas Oncology Methodist DFW | Dallas | Texas | 75230 | Recruiting |
| Texas Onc Methodist (Charlton) | Dallas | Texas | 75237 | Recruiting |
| Texas Oncology - Northeast | Denton | Texas | 76201 | Recruiting |
| Center for Oncology and Blood Disorders | Houston | Texas | 77030 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05727176, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 28, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05727176 live on ClinicalTrials.gov.